Randomized, double-blind, placebo-controlled, ascending multiple dose study of the safety, pharmacokinetics, and pharmacodynamics of sca-136 [vabicaserin] administered orally to healthy male Japanese subjects
Latest Information Update: 21 Aug 2009
At a glance
- Drugs Vabicaserin (Primary)
- Indications Depressive disorders; Schizophrenia
- Focus Adverse reactions
- Sponsors Wyeth
- 07 May 2007 New trial record.